Roche fronts $61m in DARPin deal with Molecular Partners
This article was originally published in Scrip
Roche has agreed to pay CHF55m ($61m) in up-front and initiation payments to Molecular Partners in a deal which will see the latter's novel class of small proteins – known as DARPins – conjugated to Roche drugs to treat cancer.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.